This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Inflammatory bowel disease (IBD); psoriasis	Tyrosine kinase 2 (TYK2)	<i>In vitro</i> and rodent studies suggest selectively inhibiting TYK2 could help treat IBD and psoriasis. In <i>in vitro</i> biochemical and cellular assays, an optimized aminopyridine benzamide derivative showed potent inhibition of TYK2 activity and was selective for TYK2 over off-target Janus kinases. In mice, oral treatment with the lead compound inhibited the IL-12 signaling pathway, which is associated with IBD and psoriasis. Next steps could include evaluating the TYK2 inhibitor in preclinical models for IBD and psoriasis.	Patent and licensing status undisclosed	Liang, J. <i>et al. J. Med. Chem.</i> ; published online May 14, 2013; doi:10.1021/jm400266t Contact: Jun Liang, Genentech Inc., South San Francisco, Calif. e-mail: liang.jun@gene.com
SciBX 6(24); doi:10.1038/scibx.2013.592 Published online June 20, 2013				